Anticoagulation: Low-Molecular-Weight Heparins in Renal Impairment and Obesity: Available Evidence and Clinical Practice Recommendations Across Medical and Surgical Settings

Annals of Pharmacotherapy - Tập 43 Số 6 - Trang 1064-1083 - 2009
Edith A. Nutescu1, Sarah A. Spinler2, Ann K. Wittkowsky3, William E. Dager4
1Antithrombosis Center, Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago
2Department of Pharmacy Practice, Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, Philadelphia, PA
3School of Pharmacy, University of Washington, Seattle, WA
4University of California Davis Medical Center, Sacramento, CA

Tóm tắt

Objective To develop practical recommendations for the use of low-molecular-weight heparins (LMWHs) as prophylaxis and treatment of venous thromboembolism and acute coronary syndromes in patients with impaired renal function or obesity. Data Sources Multiple MEDLINE searches were performed (November 2008) to identify studies for inclusion, using a comprehensive list of search terms including, but not limited to, LMWH, enoxaparin, dalteparin, tinzaparin, obesity, weight, renal, kidney, elderly, monitoring, and anti-Xa. Study Selection And Data Extraction Only articles published in English that were relevant for this review were included. Data Synthesis In the majority of patients, standardized prophylaxis or treatment doses of LMWHs can be used without the need for monitoring and adjusting regimens. For patients with severe renal impairment (estimated creatinine clearance [CrCl] <30 mL/min), doses of some LMWHs should be adjusted or unfractionated heparin should be used instead. CrCl should be estimated using the Cockcroft-Gault method. Differences are noted in the degree of accumulation of various LMWHs in patients with moderate-to-severe renal impairment, and thus, the degree of dose adjustment may differ among the various LMWHs. Increasing the prophylactic doses of LMWH may be appropriate in morbidly obese patients (body mass index ≥40 kg/m2). The use of total body weight is appropriate for therapeutic doses of LMWH in obese patients. Laboratory monitoring of the anticoagulation effect of LMWHs is generally not necessary, but should be considered in patients with morbid obesity (weight >190 kg), those with severe renal impairment, and those with moderate renal impairment with prolonged (>10 days) LMWH use. When anti-Xa activity is monitored, it should be determined using a chromogenic method and a calibration curve based on the LMWH used. Conclusions Additional data are needed for specific dose guiding in obese and renally impaired patients, who are often excluded from larger clinical trials. Practice recommendations are made based on available evidence and authors' clinical opinions.

Từ khóa


Tài liệu tham khảo

10.1161/01.CIR.0000136830.65073.C7

Nutescu E, 2007, Managing anticoagulation patients in the hospital. The inpatient anticoagulation service, 177

10.7326/0003-4819-144-9-200605020-00011

10.1001/archinte.160.14.2199

10.1056/NEJMoa025313

10.1161/01.CIR.0000138928.83266.24

10.1177/1076029606293692

10.1056/NEJM199909093411103

10.2106/00004623-200103000-00004

10.7326/0003-4819-134-3-200102060-00009

10.1056/NEJM199709043371002

10.1001/archinte.160.2.229

10.1016/S0140-6736(96)91270-2

10.1016/S0140-6736(99)07350-X

10.1161/01.CIR.96.1.61

10.1056/NEJM199708143370702

10.1161/01.CIR.100.15.1593

10.1001/jama.292.1.55

Ferguson JJ, 2004, JAMA, 292, 45

10.1016/S0002-8703(03)00179-0

10.1056/NEJMoa060898

10.1016/S0140-6736(01)05775-0

10.1161/01.CIR.0000081659.72985.A8

10.1016/S0002-8703(03)00121-2

10.7326/0003-4819-139-2-200307150-00013

10.1681/ASN.2004060447

10.1056/NEJMra054415

10.1080/00365590310015750

10.1001/archinte.163.3.356

10.1161/CIRCULATIONAHA.107.188209

10.1111/j.1538-7836.2006.01731.x

10.1016/j.thromres.2004.10.004

10.1016/S0049-3848(02)00031-2

10.2165/00002512-200724010-00005

10.1160/TH06-09-0513

Tincani E, 2006, Haematologica, 91, 976

10.1016/j.jcrc.2005.09.009

Schmid P, 2007, J Thromb Haemost, 5, P-T-674

10.1001/archinte.168.16.1805

10.1592/phco.2005.25.6.817

2007, Product information. Lovenox (enoxaparin sodium injection)

10.1067/mhj.2002.120774

10.1046/j.1365-2125.2003.01904.x

10.1016/j.clpt.2005.02.012

10.1177/0091270003253420

10.2165/00002018-200225100-00005

10.1055/s-0037-1614119

Barrett JS, 2001, Int J Clin Pharmacol Ther, 39, 431

10.1378/chest.125.3.856

10.1016/S0735-1097(02)02664-5

10.1093/eurheartj/ehi337

10.1016/j.jacc.2006.12.049

10.7326/0003-4819-147-5-200709040-00005

10.1053/ajkd.2002.36331

10.1160/TH07-02-0132

10.1038/ncpneph0673

10.1016/S0735-1097(99)00608-7

10.1007/s11239-007-0182-x

Warkentin TE, 2002, Can J Anaesth, 49, S11

10.1592/phco.27.10.1347

10.1016/j.ahj.2004.04.015

10.1111/j.1365-2125.2004.02253.x

10.7326/0003-4819-141-2-200407200-00007

10.1111/j.1365-2125.2007.02920.x

10.1093/eurheartj/ehm081

10.1097/01.ASN.0000145014.80714.35

10.1016/j.clinthera.2005.09.008

10.1592/phco.21.2.218.34112

10.1177/106002809202600113

10.1378/chest.127.6.2288

10.1111/j.1538-7836.2005.01342.x

Wilson SJ, 2001, Haemostasis, 31, 42

Samama MM, 1995, Thromb Haemost, 73, 977

10.1002/bjs.4068

10.1007/s00464-008-9997-6

10.1016/j.soard.2007.11.010

10.1001/archinte.165.3.341

10.1381/096089202321144522

10.1016/j.soard.2007.12.015

10.1016/j.soard.2007.09.015

10.1381/096089205774859245

Frydman A, 1996, Haemostasis, 26, 24

10.1016/0049-3848(95)00227-8

10.1093/ajhp/60.7.683

10.1007/s002280000141

10.1067/mcp.2002.127114

10.1055/s-0037-1613090

10.1111/j.1538-7836.2004.01053.x

10.1111/j.1538-7836.2005.01304.x

10.1378/chest.125.5.1616

10.1016/j.jacc.2007.02.013

2007, Product information. Fragmin (dalteparin sodium injection)

10.1345/aph.1E096

Laposata M, 1998, Arch Pathol Lab Med, 122, 799

10.1378/chest.08-0658

10.1046/j.0004-8666.2003.00034.x

10.1007/s11239-006-4383-5

10.1111/j.1540-8183.2004.04030.x

10.1182/blood.V78.9.2337.2337

10.1046/j.1365-2141.1999.01153.x

10.1532/LH96.05028

10.1055/s-0038-1647449

10.1055/s-0037-1614377

10.1016/S0272-2712(18)30347-0

10.1046/j.1365-2257.1999.00183.x

10.1016/S0735-1097(03)01053-2

10.1016/j.thromres.2004.01.006

Cavusoglu E, 2005, J Invasive Cardiol, 17, 416

10.1592/phco.2005.25.10.1341

10.1345/aph.1E524

10.1345/aph.1E118

10.1046/j.0007-1048.2001.03306.x

10.1055/s-0038-1646595

10.1055/s-0038-1653833

10.1055/s-0038-1653787

Boneu B, 2003, Sang Thrombose Vaisseaux, 15, 131

10.1378/chest.119.1_suppl.344S

Thông tin
Thông tin xuất bản

Annals of Pharmacotherapy

Tập 43 Số 6

1064-1083

Thông tin tác giả